Last 12 months
Inside the activity.
0 purchase rows · 7 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 4 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 04, 2021 Filed Jan 6, 2021 23:55 UTC |
Krognes Steve E.CFO and Treasurer
|
GrantStock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $70.86 | $0.00 |
DisclosureSEC source: 0001209191-21-002352 · doc4.xml · derivative · entry 2 Krognes Steve E. · CIK 0001666236 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2031-01-03 F3 · derivative.exercise_date: 25% of the shares subject to the option shall vest on January 4, 2022, and 1/48 of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 23:55 UTC |
Krognes Steve E.CFO and Treasurer
|
GrantRestricted Stock Units · Derivative | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-002352 · doc4.xml · derivative · entry 1 Krognes Steve E. · CIK 0001666236 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F2 · derivative.exercise_date: 25% of the restricted stock units shall vest on January 4, 2022 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. F2 · derivative.expiration_date: 25% of the restricted stock units shall vest on January 4, 2022 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 23:54 UTC |
Ho CaroleChief Medical Officer
|
GrantStock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $70.86 | $0.00 |
DisclosureSEC source: 0001209191-21-002351 · doc4.xml · derivative · entry 2 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2031-01-03 F3 · derivative.exercise_date: 25% of the shares subject to the option shall vest on January 4, 2022, and 1/48 of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 23:54 UTC |
Ho CaroleChief Medical Officer
|
GrantRestricted Stock Units · Derivative | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-002351 · doc4.xml · derivative · entry 1 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F2 · derivative.exercise_date: 25% of the restricted stock units shall vest on January 4, 2022 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. F2 · derivative.expiration_date: 25% of the restricted stock units shall vest on January 4, 2022 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| December 21, 2020 Filed Dec 24, 2020 02:52 UTC |
Schenkein David PDirector
|
SaleCommon Stock | 5,000 | $90.01 | $450,027.00 |
DisclosureSEC source: 0001209191-20-065134 · doc4.xml · nonDerivative · entry 2 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 26,232 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The sale price reported in column 4 of Table I represents the weighted average price of the shares sold ranging from $90.00 to $90.02 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F4 · balance_after: This number is restated pursuant to an internal review of the Reporting Person's holdings, and reflects the consolidation of shares between trusts associated with the Reporting Person. F5 · ownership.nature: The shares are held of record by the David P. Schenkein 2004 Revocable Trust, for which the Reporting Person serves as a trustee. Read SEC document |
| December 21, 2020 Filed Dec 24, 2020 02:52 UTC |
Schenkein David PDirector
|
SaleCommon Stock | 25,000 | $90.06 | $2,251,555.00 |
DisclosureSEC source: 0001209191-20-065134 · doc4.xml · nonDerivative · entry 1 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average price of the shares sold ranging from $90.00 to $90.38 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 23:44 UTC |
BRATTON DOUGLAS K10% owner
Neuro Line Partners LP10% owner
Bratton Capital Management, L.P.10% owner
Bratton Capital Inc.10% owner
|
OtherCommon Stock | 383,411 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-035043 · doc4.xml · nonDerivative · entry 1 BRATTON DOUGLAS K · CIK 0001281933 · 10% owner Neuro Line Partners LP · CIK 0001723842 · 10% owner Bratton Capital Management, L.P. · CIK 0001723787 · 10% owner Bratton Capital Inc. · CIK 0001723783 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Neuro Line Partners, L.P. Disclosed balance after: 0 F1 · price: Represents a pro rata in-kind distribution of shares of common stock of Denali Therapeutics Inc. from Neuro Line Partners, L.P. ("Neuro Line") to limited partners of Neuro Line without consideration, including to an entity controlled by Douglas K. Bratton. F2 · ownership.nature: These shares of common stock of the Issuer were held directly by Neuro Line Partners, L.P. ("Neuro Line"). The general partner of Neuro Line is Bratton Capital Management, L.P. ("Bratton Capital Management"). The general partner of Bratton Capital Management is Bratton Capital, Inc. ("Bratton Capital"). Douglas K. Bratton is the sole director of Bratton Capital. Neuro Line is ultimately controlled by Mr. Bratton and Mr. Bratton had voting and investment power over all securities that were held by Neuro Line. F3 · ownership.nature: (Continued from footnote 2) In addition, Bratton Capital Management, Bratton Capital, and Mr. Bratton may have been deemed to have had a pecuniary interest in a portion of the securities that were held by Neuro Line due to Bratton Capital Management's right to receive performance-based allocations and Bratton Capital Management and Mr. Bratton may have been deemed to have had a pecuniary interest in a portion of the securities that were held by Neuro Line through direct or indirect limited partner and/or general partner interests in Neuro Line. Bratton Capital Management, Bratton Capital and Mr. Bratton may each have been deemed to beneficially own the securities held by Neuro Line. Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Read SEC document |
| December 14, 2020 Filed Dec 15, 2020 21:47 UTC |
BRATTON DOUGLAS K10% owner
Neuro Line Partners LP10% owner
Bratton Capital Management, L.P.10% owner
Bratton Capital Inc.10% owner
|
SaleCommon Stock | 876 | $81.13 | $71,068.22 |
DisclosureSEC source: 0000899243-20-033903 · doc4.xml · nonDerivative · entry 3 BRATTON DOUGLAS K · CIK 0001281933 · 10% owner Neuro Line Partners LP · CIK 0001723842 · 10% owner Bratton Capital Management, L.P. · CIK 0001723787 · 10% owner Bratton Capital Inc. · CIK 0001723783 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Neuro Line Partners, L.P. Disclosed balance after: 383,411 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.115 to $81.18, inclusive. F2 · ownership.nature: These shares of common stock of the Issuer are held directly by Neuro Line Partners, L.P. ("Neuro Line"). The general partner of Neuro Line is Bratton Capital Management, L.P. ("Bratton Capital Management"). The general partner of Bratton Capital Management is Bratton Capital, Inc. ("Bratton Capital"). Douglas K. Bratton is the sole director of Bratton Capital. Neuro Line is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by Neuro Line. In addition, Bratton Capital Management, Bratton Capital, and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line due to Bratton Capital Management's right to receive performance-based allocations and Bratton Capital Management and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line through direct or indirect limited partner and/or general partner interests in Neuro Line. F3 · ownership.nature: (Continued from Footnote 2) Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to beneficially own the securities held by Neuro Line. Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Read SEC document |
| December 14, 2020 Filed Dec 15, 2020 21:47 UTC |
BRATTON DOUGLAS K10% owner
Neuro Line Partners LP10% owner
Bratton Capital Management, L.P.10% owner
Bratton Capital Inc.10% owner
|
SaleCommon Stock | 16,949 | $80.35 | $1,361,774.18 |
DisclosureSEC source: 0000899243-20-033903 · doc4.xml · nonDerivative · entry 2 BRATTON DOUGLAS K · CIK 0001281933 · 10% owner Neuro Line Partners LP · CIK 0001723842 · 10% owner Bratton Capital Management, L.P. · CIK 0001723787 · 10% owner Bratton Capital Inc. · CIK 0001723783 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Neuro Line Partners, L.P. Disclosed balance after: 384,287 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.10 to $80.99, inclusive. F2 · ownership.nature: These shares of common stock of the Issuer are held directly by Neuro Line Partners, L.P. ("Neuro Line"). The general partner of Neuro Line is Bratton Capital Management, L.P. ("Bratton Capital Management"). The general partner of Bratton Capital Management is Bratton Capital, Inc. ("Bratton Capital"). Douglas K. Bratton is the sole director of Bratton Capital. Neuro Line is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by Neuro Line. In addition, Bratton Capital Management, Bratton Capital, and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line due to Bratton Capital Management's right to receive performance-based allocations and Bratton Capital Management and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line through direct or indirect limited partner and/or general partner interests in Neuro Line. F3 · ownership.nature: (Continued from Footnote 2) Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to beneficially own the securities held by Neuro Line. Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Read SEC document |
| December 11, 2020 Filed Dec 15, 2020 21:47 UTC |
BRATTON DOUGLAS K10% owner
Neuro Line Partners LP10% owner
Bratton Capital Management, L.P.10% owner
Bratton Capital Inc.10% owner
|
SaleCommon Stock | 46,799 | $80.05 | $3,746,442.47 |
DisclosureSEC source: 0000899243-20-033903 · doc4.xml · nonDerivative · entry 1 BRATTON DOUGLAS K · CIK 0001281933 · 10% owner Neuro Line Partners LP · CIK 0001723842 · 10% owner Bratton Capital Management, L.P. · CIK 0001723787 · 10% owner Bratton Capital Inc. · CIK 0001723783 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Neuro Line Partners, L.P. Disclosed balance after: 401,236 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.83 to $80.31, inclusive. The reporting persons undertake to provide to Denali Therapeutics Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (4) and (5) to this Form 4. F2 · ownership.nature: These shares of common stock of the Issuer are held directly by Neuro Line Partners, L.P. ("Neuro Line"). The general partner of Neuro Line is Bratton Capital Management, L.P. ("Bratton Capital Management"). The general partner of Bratton Capital Management is Bratton Capital, Inc. ("Bratton Capital"). Douglas K. Bratton is the sole director of Bratton Capital. Neuro Line is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by Neuro Line. In addition, Bratton Capital Management, Bratton Capital, and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line due to Bratton Capital Management's right to receive performance-based allocations and Bratton Capital Management and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line through direct or indirect limited partner and/or general partner interests in Neuro Line. F3 · ownership.nature: (Continued from Footnote 2) Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to beneficially own the securities held by Neuro Line. Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Read SEC document |
| November 12, 2020 Filed Nov 13, 2020 22:13 UTC |
Schenkein David PDirector
|
SaleCommon Stock | 30,000 | $70.05 | $2,101,590.00 |
DisclosureSEC source: 0001209191-20-058334 · doc4.xml · nonDerivative · entry 1 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $70.00 to $70.305 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 10, 2020 Filed Nov 12, 2020 21:21 UTC |
Schenkein David PDirector
|
SaleCommon Stock | 10,000 | $60.03 | $600,310.00 |
DisclosureSEC source: 0001209191-20-057936 · doc4.xml · nonDerivative · entry 1 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $60.00 to $60.19 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 22:53 UTC |
Schenkein David PDirector
|
SaleCommon Stock | 10,000 | $50.18 | $501,830.00 |
DisclosureSEC source: 0001209191-20-057336 · doc4.xml · nonDerivative · entry 1 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $50.00 to $50.71 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| October 09, 2020 Filed Oct 13, 2020 22:45 UTC |
Ho CaroleChief Medical Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $5.28 | $0.00 |
DisclosureSEC source: 0001209191-20-054727 · doc4.xml · derivative · entry 9 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,240 Underlying: Common Stock · 30,000 shares Expires 2027-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Of the total 187,500 shares granted, 25% of the shares subject to the option vested on March 8, 2018 and an additional 1/48 of the shares vest monthly thereafter. Read SEC document |
| October 09, 2020 Filed Oct 13, 2020 22:45 UTC |
Ho CaroleChief Medical Officer
|
SaleCommon Stock | 19,535 | $41.51 | $810,897.85 |
DisclosureSEC source: 0001209191-20-054727 · doc4.xml · nonDerivative · entry 5 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 166,617 F2 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $41.11 to $41.81 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F1 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| October 09, 2020 Filed Oct 13, 2020 22:45 UTC |
Ho CaroleChief Medical Officer
|
SaleCommon Stock | 10,465 | $40.68 | $425,716.20 |
DisclosureSEC source: 0001209191-20-054727 · doc4.xml · nonDerivative · entry 4 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 186,152 F2 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $40.11 to $41.09 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F1 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| October 09, 2020 Filed Oct 13, 2020 22:45 UTC |
Ho CaroleChief Medical Officer
|
Exercise / conversionCommon Stock | 30,000 | $5.28 | $158,400.00 |
DisclosureSEC source: 0001209191-20-054727 · doc4.xml · nonDerivative · entry 3 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 196,617 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| October 08, 2020 Filed Oct 13, 2020 22:45 UTC |
Ho CaroleChief Medical Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 9,886 | $0.00 Strike: $5.28 | $0.00 |
DisclosureSEC source: 0001209191-20-054727 · doc4.xml · derivative · entry 8 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,240 Underlying: Common Stock · 9,886 shares Expires 2027-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Of the total 187,500 shares granted, 25% of the shares subject to the option vested on March 8, 2018 and an additional 1/48 of the shares vest monthly thereafter. Read SEC document |
| October 08, 2020 Filed Oct 13, 2020 22:45 UTC |
Ho CaroleChief Medical Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 13,020 | $0.00 Strike: $5.28 | $0.00 |
DisclosureSEC source: 0001209191-20-054727 · doc4.xml · derivative · entry 7 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,035 Underlying: Common Stock · 13,020 shares Expires 2026-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Of the total 125,000 shares granted, 25% of the shares subject to the option vested on July 2, 2017 and an additional 1/48 of the shares vest monthly thereafter. Read SEC document |
| October 08, 2020 Filed Oct 13, 2020 22:45 UTC |
Ho CaroleChief Medical Officer
|
SaleCommon Stock | 22,906 | $40.12 | $918,988.72 |
DisclosureSEC source: 0001209191-20-054727 · doc4.xml · nonDerivative · entry 2 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 166,617 F2 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $40.00 to $40.32 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F1 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| October 08, 2020 Filed Oct 13, 2020 22:45 UTC |
Ho CaroleChief Medical Officer
|
Exercise / conversionCommon Stock | 22,906 | $5.28 | $120,943.68 |
DisclosureSEC source: 0001209191-20-054727 · doc4.xml · nonDerivative · entry 1 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 189,523 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| September 10, 2020 Filed Sep 15, 2020 01:38 UTC |
Ho CaroleChief Medical Officer
|
SaleCommon Stock | 3,689 | $31.00 | $114,359.00 |
DisclosureSEC source: 0001209191-20-050357 · doc4.xml · nonDerivative · entry 1 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 165,141 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| August 21, 2020 Filed Aug 25, 2020 00:37 UTC |
Schuth Alexander O.COO and Secretary
|
Tax withholdingCommon Stock | 1,954 | $32.88 | $64,247.52 |
DisclosureSEC source: 0001209191-20-048174 · doc4.xml · nonDerivative · entry 2 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 614,562 F3 · kind: Shares withheld to satisfy the tax obligations by the reporting person in connection with the vesting of restricted stock units. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $32.82 to $32.885 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F2 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| August 21, 2020 Filed Aug 25, 2020 00:38 UTC |
Ho CaroleChief Medical Officer
|
Tax withholdingCommon Stock | 1,954 | $32.88 | $64,247.52 |
DisclosureSEC source: 0001209191-20-048175 · doc4.xml · nonDerivative · entry 2 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,511 F2 · kind: Shares withheld to satisfy the tax obligations by the reporting person in connection with the vesting of restricted stock units. F3 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $32.835 to $32.885 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| August 21, 2020 Filed Aug 25, 2020 00:37 UTC |
Krognes Steve E.CFO and Treasurer
|
Tax withholdingCommon Stock | 1,954 | $32.87 | $64,227.98 |
DisclosureSEC source: 0001209191-20-048173 · doc4.xml · nonDerivative · entry 2 Krognes Steve E. · CIK 0001666236 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,006,511 F3 · kind: Shares withheld to satisfy the tax obligations by the reporting person in connection with the vesting of restricted stock units. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $32.835 to $32.89 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F2 · ownership.nature: The shares are held of record by The Steve Edward Krognes Revocable Trust U/A DTD 01/25/2016, for which the Reporting Person serves as trustee. Read SEC document |
| August 21, 2020 Filed Nov 30, 2020 23:11 UTC Amendment |
Schuth Alexander O.COO and Secretary
|
Tax withholdingCommon Stock | 1,954 | $32.88 | $64,247.52 |
DisclosureSEC source: 0001209191-20-060789 · doc4a.xml · nonDerivative · entry 2 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 614,562 F3 · kind: Shares withheld to satisfy the tax obligations by the reporting person in connection with the vesting of restricted stock units. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $32.82 to $32.885 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F2 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| August 20, 2020 Filed Aug 25, 2020 00:37 UTC |
Schuth Alexander O.COO and Secretary
|
Exercise / conversionRestricted Stock Units · Derivative | 5,643 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-048174 · doc4.xml · derivative · entry 4 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,643 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Common Stock of the Issuer. F5 · derivative.exercise_date: 50% of the shares vested on August 20, 2019 and the remaining 50% of the shares vested on August 20, 2020. F5 · derivative.expiration_date: 50% of the shares vested on August 20, 2019 and the remaining 50% of the shares vested on August 20, 2020. Read SEC document |
| August 20, 2020 Filed Aug 25, 2020 00:37 UTC |
Schuth Alexander O.COO and Secretary
|
Exercise / conversionCommon Stock | 5,643 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-048174 · doc4.xml · nonDerivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 616,516 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Common Stock of the Issuer. F2 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| August 20, 2020 Filed Aug 25, 2020 00:38 UTC |
Ho CaroleChief Medical Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 5,643 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-048175 · doc4.xml · derivative · entry 5 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,643 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Common Stock of the Issuer. F6 · derivative.exercise_date: 50% of the shares vested on August 20, 2019 and the remaining 50% of the shares vested on August 20, 2020. F6 · derivative.expiration_date: 50% of the shares vested on August 20, 2019 and the remaining 50% of the shares vested on August 20, 2020. Read SEC document |
| August 20, 2020 Filed Aug 25, 2020 00:38 UTC |
Ho CaroleChief Medical Officer
|
Exercise / conversionCommon Stock | 5,643 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-048175 · doc4.xml · nonDerivative · entry 1 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,465 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Common Stock of the Issuer. Read SEC document |
| August 20, 2020 Filed Aug 25, 2020 00:37 UTC |
Krognes Steve E.CFO and Treasurer
|
Exercise / conversionRestricted Stock Units · Derivative | 5,643 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-048173 · doc4.xml · derivative · entry 4 Krognes Steve E. · CIK 0001666236 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,643 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Common Stock of the Issuer. F5 · derivative.exercise_date: 50% of the shares vested on August 20, 2019 and the remaining 50% of the shares vested on August 20, 2020. F5 · derivative.expiration_date: 50% of the shares vested on August 20, 2019 and the remaining 50% of the shares vested on August 20, 2020. Read SEC document |
| August 20, 2020 Filed Aug 25, 2020 00:37 UTC |
Krognes Steve E.CFO and Treasurer
|
Exercise / conversionCommon Stock | 5,643 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-048173 · doc4.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,008,465 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Common Stock of the Issuer. F2 · ownership.nature: The shares are held of record by The Steve Edward Krognes Revocable Trust U/A DTD 01/25/2016, for which the Reporting Person serves as trustee. Read SEC document |
| August 20, 2020 Filed Nov 30, 2020 23:11 UTC Amendment |
Schuth Alexander O.COO and Secretary
|
Exercise / conversionCommon Stock | 5,643 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-060789 · doc4a.xml · nonDerivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 616,516 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Common Stock of the Issuer. F2 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:14 UTC |
Watts Ryan J.Director · President and CEO
|
GrantRestricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-047792 · doc4.xml · derivative · entry 1 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F2 · derivative.exercise_date: 25% of the restricted stock units shall vest on August 18, 2021 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. F2 · derivative.expiration_date: 25% of the restricted stock units shall vest on August 18, 2021 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:19 UTC |
Schuth Alexander O.COO and Secretary
|
GrantRestricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-047794 · doc4.xml · derivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F2 · derivative.exercise_date: 25% of the restricted stock units shall vest on August 18, 2021 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. F2 · derivative.expiration_date: 25% of the restricted stock units shall vest on August 18, 2021 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:20 UTC |
Ho CaroleChief Medical Officer
|
GrantRestricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-047795 · doc4.xml · derivative · entry 1 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F2 · derivative.exercise_date: 25% of the restricted stock units shall vest on August 18, 2021 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. F2 · derivative.expiration_date: 25% of the restricted stock units shall vest on August 18, 2021 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:17 UTC |
Krognes Steve E.CFO and Treasurer
|
GrantRestricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-047793 · doc4.xml · derivative · entry 1 Krognes Steve E. · CIK 0001666236 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F2 · derivative.exercise_date: 25% of the restricted stock units shall vest on August 18, 2021 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. F2 · derivative.expiration_date: 25% of the restricted stock units shall vest on August 18, 2021 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 16:50 UTC |
BRATTON DOUGLAS K10% owner
AKDL, L.P.10% owner
Crestline SI (GP), L.P.10% owner
Crestline Investors, Inc.10% owner
Crestline Management, L.P.10% owner
|
SaleCommon Stock | 1,443,247 | $31.65 | $45,678,767.55 |
DisclosureSEC source: 0000899243-20-022430 · doc4.xml · nonDerivative · entry 1 BRATTON DOUGLAS K · CIK 0001281933 · 10% owner AKDL, L.P. · CIK 0001716958 · 10% owner Crestline SI (GP), L.P. · CIK 0001626597 · 10% owner Crestline Investors, Inc. · CIK 0001626596 · 10% owner Crestline Management, LP · CIK 0001536054 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By AKDL, L.P. Disclosed balance after: 12,201,634 F1 · ownership.nature: These shares of common stock of Denali Therapeutics Inc. (the "Issuer") are held directly by AKDL, L.P. ("AKDL"). The general partner of AKDL is Crestline SI (GP), L.P. ("Crestline SI") and the investment manager of AKDL is Crestline Management, L.P. ("Crestline Management"). Crestline Investors, Inc. ("Crestline") is the general partner of both Crestline SI and Crestline Management. Douglas K. Bratton is the sole director of Crestline. AKDL is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by AKDL. In addition, Crestline SI, Crestline and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by AKDL through direct or indirect limited partner interests, including limited partner profit interests, and/or general partner interests in AKDL. F2 · ownership.nature: (Continued from footnote 1) Crestline SI, Crestline Management, Crestline and Mr. Bratton may each be deemed to beneficially own the securities held by AKDL. Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Read SEC document |
| June 30, 2020 Filed Jun 30, 2020 23:17 UTC |
BRATTON DOUGLAS K10% owner
Neuro Line Partners LP10% owner
Bratton Capital Management, L.P.10% owner
Bratton Capital Inc.10% owner
|
SaleCommon Stock | 200 | $24.34 | $4,868.00 |
DisclosureSEC source: 0000899243-20-018024 · doc4.xml · nonDerivative · entry 6 BRATTON DOUGLAS K · CIK 0001281933 · 10% owner Neuro Line Partners LP · CIK 0001723842 · 10% owner Bratton Capital Management, L.P. · CIK 0001723787 · 10% owner Bratton Capital Inc. · CIK 0001723783 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Neuro Line Partners, L.P. Disclosed balance after: 448,035 F2 · ownership.nature: These shares of common stock of the Issuer are held directly by Neuro Line Partners, L.P. ("Neuro Line"). The general partner of Neuro Line is Bratton Capital Management, L.P. ("Bratton Capital Management"). The general partner of Bratton Capital Management is Bratton Capital, Inc. ("Bratton Capital"). Douglas K. Bratton is the sole director of Bratton Capital. Neuro Line is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by Neuro Line. In addition, Bratton Capital Management, Bratton Capital, and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line due to Bratton Capital Management's right to receive performance-based allocations and Bratton Capital Management and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line through direct or indirect limited partner and/or general partner interests in Neuro Line. F3 · ownership.nature: (Continued from Footnote 2) Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to beneficially own the securities held by Neuro Line. Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Read SEC document |
| June 30, 2020 Filed Jun 30, 2020 23:17 UTC |
BRATTON DOUGLAS K10% owner
Neuro Line Partners LP10% owner
Bratton Capital Management, L.P.10% owner
Bratton Capital Inc.10% owner
|
SaleCommon Stock | 45,145 | $24.01 | $1,083,732.81 |
DisclosureSEC source: 0000899243-20-018024 · doc4.xml · nonDerivative · entry 5 BRATTON DOUGLAS K · CIK 0001281933 · 10% owner Neuro Line Partners LP · CIK 0001723842 · 10% owner Bratton Capital Management, L.P. · CIK 0001723787 · 10% owner Bratton Capital Inc. · CIK 0001723783 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Neuro Line Partners, L.P. Disclosed balance after: 448,235 F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.34 to $24.33, inclusive. F2 · ownership.nature: These shares of common stock of the Issuer are held directly by Neuro Line Partners, L.P. ("Neuro Line"). The general partner of Neuro Line is Bratton Capital Management, L.P. ("Bratton Capital Management"). The general partner of Bratton Capital Management is Bratton Capital, Inc. ("Bratton Capital"). Douglas K. Bratton is the sole director of Bratton Capital. Neuro Line is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by Neuro Line. In addition, Bratton Capital Management, Bratton Capital, and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line due to Bratton Capital Management's right to receive performance-based allocations and Bratton Capital Management and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line through direct or indirect limited partner and/or general partner interests in Neuro Line. F3 · ownership.nature: (Continued from Footnote 2) Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to beneficially own the securities held by Neuro Line. Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Read SEC document |
| June 29, 2020 Filed Jun 30, 2020 23:17 UTC |
BRATTON DOUGLAS K10% owner
Neuro Line Partners LP10% owner
Bratton Capital Management, L.P.10% owner
Bratton Capital Inc.10% owner
|
SaleCommon Stock | 20,771 | $24.50 | $508,974.66 |
DisclosureSEC source: 0000899243-20-018024 · doc4.xml · nonDerivative · entry 4 BRATTON DOUGLAS K · CIK 0001281933 · 10% owner Neuro Line Partners LP · CIK 0001723842 · 10% owner Bratton Capital Management, L.P. · CIK 0001723787 · 10% owner Bratton Capital Inc. · CIK 0001723783 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Neuro Line Partners, L.P. Disclosed balance after: 493,380 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.36 to $24.76, inclusive. F2 · ownership.nature: These shares of common stock of the Issuer are held directly by Neuro Line Partners, L.P. ("Neuro Line"). The general partner of Neuro Line is Bratton Capital Management, L.P. ("Bratton Capital Management"). The general partner of Bratton Capital Management is Bratton Capital, Inc. ("Bratton Capital"). Douglas K. Bratton is the sole director of Bratton Capital. Neuro Line is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by Neuro Line. In addition, Bratton Capital Management, Bratton Capital, and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line due to Bratton Capital Management's right to receive performance-based allocations and Bratton Capital Management and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line through direct or indirect limited partner and/or general partner interests in Neuro Line. F3 · ownership.nature: (Continued from Footnote 2) Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to beneficially own the securities held by Neuro Line. Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Read SEC document |
| June 29, 2020 Filed Jun 30, 2020 23:17 UTC |
BRATTON DOUGLAS K10% owner
Neuro Line Partners LP10% owner
Bratton Capital Management, L.P.10% owner
Bratton Capital Inc.10% owner
|
SaleCommon Stock | 61,807 | $23.84 | $1,473,398.53 |
DisclosureSEC source: 0000899243-20-018024 · doc4.xml · nonDerivative · entry 3 BRATTON DOUGLAS K · CIK 0001281933 · 10% owner Neuro Line Partners LP · CIK 0001723842 · 10% owner Bratton Capital Management, L.P. · CIK 0001723787 · 10% owner Bratton Capital Inc. · CIK 0001723783 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Neuro Line Partners, L.P. Disclosed balance after: 514,151 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.36 to $24.355, inclusive. F2 · ownership.nature: These shares of common stock of the Issuer are held directly by Neuro Line Partners, L.P. ("Neuro Line"). The general partner of Neuro Line is Bratton Capital Management, L.P. ("Bratton Capital Management"). The general partner of Bratton Capital Management is Bratton Capital, Inc. ("Bratton Capital"). Douglas K. Bratton is the sole director of Bratton Capital. Neuro Line is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by Neuro Line. In addition, Bratton Capital Management, Bratton Capital, and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line due to Bratton Capital Management's right to receive performance-based allocations and Bratton Capital Management and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line through direct or indirect limited partner and/or general partner interests in Neuro Line. F3 · ownership.nature: (Continued from Footnote 2) Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to beneficially own the securities held by Neuro Line. Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Read SEC document |
| June 26, 2020 Filed Jun 30, 2020 23:17 UTC |
BRATTON DOUGLAS K10% owner
Neuro Line Partners LP10% owner
Bratton Capital Management, L.P.10% owner
Bratton Capital Inc.10% owner
|
SaleCommon Stock | 13,604 | $24.67 | $335,636.53 |
DisclosureSEC source: 0000899243-20-018024 · doc4.xml · nonDerivative · entry 2 BRATTON DOUGLAS K · CIK 0001281933 · 10% owner Neuro Line Partners LP · CIK 0001723842 · 10% owner Bratton Capital Management, L.P. · CIK 0001723787 · 10% owner Bratton Capital Inc. · CIK 0001723783 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Neuro Line Partners, L.P. Disclosed balance after: 575,958 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.49 to $24.91, inclusive. F2 · ownership.nature: These shares of common stock of the Issuer are held directly by Neuro Line Partners, L.P. ("Neuro Line"). The general partner of Neuro Line is Bratton Capital Management, L.P. ("Bratton Capital Management"). The general partner of Bratton Capital Management is Bratton Capital, Inc. ("Bratton Capital"). Douglas K. Bratton is the sole director of Bratton Capital. Neuro Line is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by Neuro Line. In addition, Bratton Capital Management, Bratton Capital, and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line due to Bratton Capital Management's right to receive performance-based allocations and Bratton Capital Management and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line through direct or indirect limited partner and/or general partner interests in Neuro Line. F3 · ownership.nature: (Continued from Footnote 2) Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to beneficially own the securities held by Neuro Line. Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Read SEC document |
| June 26, 2020 Filed Jun 30, 2020 23:17 UTC |
BRATTON DOUGLAS K10% owner
Neuro Line Partners LP10% owner
Bratton Capital Management, L.P.10% owner
Bratton Capital Inc.10% owner
|
SaleCommon Stock | 108,473 | $23.84 | $2,586,441.06 |
DisclosureSEC source: 0000899243-20-018024 · doc4.xml · nonDerivative · entry 1 BRATTON DOUGLAS K · CIK 0001281933 · 10% owner Neuro Line Partners LP · CIK 0001723842 · 10% owner Bratton Capital Management, L.P. · CIK 0001723787 · 10% owner Bratton Capital Inc. · CIK 0001723783 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Neuro Line Partners, L.P. Disclosed balance after: 589,562 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.485 to $24.48, inclusive. The reporting persons undertake to provide to Denali Therapeutics Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (4), (5), (6) and (7) to this Form 4. F2 · ownership.nature: These shares of common stock of the Issuer are held directly by Neuro Line Partners, L.P. ("Neuro Line"). The general partner of Neuro Line is Bratton Capital Management, L.P. ("Bratton Capital Management"). The general partner of Bratton Capital Management is Bratton Capital, Inc. ("Bratton Capital"). Douglas K. Bratton is the sole director of Bratton Capital. Neuro Line is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by Neuro Line. In addition, Bratton Capital Management, Bratton Capital, and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line due to Bratton Capital Management's right to receive performance-based allocations and Bratton Capital Management and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line through direct or indirect limited partner and/or general partner interests in Neuro Line. F3 · ownership.nature: (Continued from Footnote 2) Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to beneficially own the securities held by Neuro Line. Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Read SEC document |
| June 23, 2020 Filed Jun 23, 2020 21:41 UTC |
BRATTON DOUGLAS K10% owner
Neuro Line Partners LP10% owner
Bratton Capital Management, L.P.10% owner
Bratton Capital Inc.10% owner
|
SaleCommon Stock | 3,247 | $26.19 | $85,027.89 |
DisclosureSEC source: 0000899243-20-017498 · doc4.xml · nonDerivative · entry 6 BRATTON DOUGLAS K · CIK 0001281933 · 10% owner Neuro Line Partners LP · CIK 0001723842 · 10% owner Bratton Capital Management, L.P. · CIK 0001723787 · 10% owner Bratton Capital Inc. · CIK 0001723783 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Neuro Line Partners, L.P. Disclosed balance after: 698,035 F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.105 to $26.32, inclusive. F2 · ownership.nature: These shares of common stock of the Issuer are held directly by Neuro Line Partners, L.P. ("Neuro Line"). The general partner of Neuro Line is Bratton Capital Management, L.P. ("Bratton Capital Management"). The general partner of Bratton Capital Management is Bratton Capital, Inc. ("Bratton Capital"). Douglas K. Bratton is the sole director of Bratton Capital. Neuro Line is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by Neuro Line. F3 · ownership.nature: (Continued from Footnote 2) In addition, Bratton Capital Management, Bratton Capital, and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line due to Bratton Capital Management's right to receive performance-based allocations and Bratton Capital Management and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line through direct or indirect limited partner and/or general partner interests in Neuro Line. Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to beneficially own the securities held by Neuro Line. Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Read SEC document |
| June 23, 2020 Filed Jun 23, 2020 21:41 UTC |
BRATTON DOUGLAS K10% owner
Neuro Line Partners LP10% owner
Bratton Capital Management, L.P.10% owner
Bratton Capital Inc.10% owner
|
SaleCommon Stock | 16,777 | $25.69 | $430,940.73 |
DisclosureSEC source: 0000899243-20-017498 · doc4.xml · nonDerivative · entry 5 BRATTON DOUGLAS K · CIK 0001281933 · 10% owner Neuro Line Partners LP · CIK 0001723842 · 10% owner Bratton Capital Management, L.P. · CIK 0001723787 · 10% owner Bratton Capital Inc. · CIK 0001723783 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Neuro Line Partners, L.P. Disclosed balance after: 701,282 F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.09 to $26.085, inclusive. F2 · ownership.nature: These shares of common stock of the Issuer are held directly by Neuro Line Partners, L.P. ("Neuro Line"). The general partner of Neuro Line is Bratton Capital Management, L.P. ("Bratton Capital Management"). The general partner of Bratton Capital Management is Bratton Capital, Inc. ("Bratton Capital"). Douglas K. Bratton is the sole director of Bratton Capital. Neuro Line is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by Neuro Line. F3 · ownership.nature: (Continued from Footnote 2) In addition, Bratton Capital Management, Bratton Capital, and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line due to Bratton Capital Management's right to receive performance-based allocations and Bratton Capital Management and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line through direct or indirect limited partner and/or general partner interests in Neuro Line. Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to beneficially own the securities held by Neuro Line. Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Read SEC document |
| June 22, 2020 Filed Jun 23, 2020 21:41 UTC |
BRATTON DOUGLAS K10% owner
Neuro Line Partners LP10% owner
Bratton Capital Management, L.P.10% owner
Bratton Capital Inc.10% owner
|
SaleCommon Stock | 24,683 | $25.12 | $619,960.44 |
DisclosureSEC source: 0000899243-20-017498 · doc4.xml · nonDerivative · entry 4 BRATTON DOUGLAS K · CIK 0001281933 · 10% owner Neuro Line Partners LP · CIK 0001723842 · 10% owner Bratton Capital Management, L.P. · CIK 0001723787 · 10% owner Bratton Capital Inc. · CIK 0001723783 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Neuro Line Partners, L.P. Disclosed balance after: 718,059 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.94 to $25.34, inclusive. F2 · ownership.nature: These shares of common stock of the Issuer are held directly by Neuro Line Partners, L.P. ("Neuro Line"). The general partner of Neuro Line is Bratton Capital Management, L.P. ("Bratton Capital Management"). The general partner of Bratton Capital Management is Bratton Capital, Inc. ("Bratton Capital"). Douglas K. Bratton is the sole director of Bratton Capital. Neuro Line is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by Neuro Line. F3 · ownership.nature: (Continued from Footnote 2) In addition, Bratton Capital Management, Bratton Capital, and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line due to Bratton Capital Management's right to receive performance-based allocations and Bratton Capital Management and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line through direct or indirect limited partner and/or general partner interests in Neuro Line. Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to beneficially own the securities held by Neuro Line. Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Read SEC document |
| June 22, 2020 Filed Jun 23, 2020 21:41 UTC |
BRATTON DOUGLAS K10% owner
Neuro Line Partners LP10% owner
Bratton Capital Management, L.P.10% owner
Bratton Capital Inc.10% owner
|
SaleCommon Stock | 65,373 | $24.66 | $1,611,941.28 |
DisclosureSEC source: 0000899243-20-017498 · doc4.xml · nonDerivative · entry 3 BRATTON DOUGLAS K · CIK 0001281933 · 10% owner Neuro Line Partners LP · CIK 0001723842 · 10% owner Bratton Capital Management, L.P. · CIK 0001723787 · 10% owner Bratton Capital Inc. · CIK 0001723783 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Neuro Line Partners, L.P. Disclosed balance after: 742,742 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.94 to $24.93, inclusive. F2 · ownership.nature: These shares of common stock of the Issuer are held directly by Neuro Line Partners, L.P. ("Neuro Line"). The general partner of Neuro Line is Bratton Capital Management, L.P. ("Bratton Capital Management"). The general partner of Bratton Capital Management is Bratton Capital, Inc. ("Bratton Capital"). Douglas K. Bratton is the sole director of Bratton Capital. Neuro Line is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by Neuro Line. F3 · ownership.nature: (Continued from Footnote 2) In addition, Bratton Capital Management, Bratton Capital, and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line due to Bratton Capital Management's right to receive performance-based allocations and Bratton Capital Management and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line through direct or indirect limited partner and/or general partner interests in Neuro Line. Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to beneficially own the securities held by Neuro Line. Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Read SEC document |
| June 19, 2020 Filed Jun 23, 2020 21:41 UTC |
BRATTON DOUGLAS K10% owner
Neuro Line Partners LP10% owner
Bratton Capital Management, L.P.10% owner
Bratton Capital Inc.10% owner
|
SaleCommon Stock | 62,439 | $25.00 | $1,560,850.12 |
DisclosureSEC source: 0000899243-20-017498 · doc4.xml · nonDerivative · entry 2 BRATTON DOUGLAS K · CIK 0001281933 · 10% owner Neuro Line Partners LP · CIK 0001723842 · 10% owner Bratton Capital Management, L.P. · CIK 0001723787 · 10% owner Bratton Capital Inc. · CIK 0001723783 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Neuro Line Partners, L.P. Disclosed balance after: 808,115 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.61 to $25.60, inclusive. F2 · ownership.nature: These shares of common stock of the Issuer are held directly by Neuro Line Partners, L.P. ("Neuro Line"). The general partner of Neuro Line is Bratton Capital Management, L.P. ("Bratton Capital Management"). The general partner of Bratton Capital Management is Bratton Capital, Inc. ("Bratton Capital"). Douglas K. Bratton is the sole director of Bratton Capital. Neuro Line is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by Neuro Line. F3 · ownership.nature: (Continued from Footnote 2) In addition, Bratton Capital Management, Bratton Capital, and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line due to Bratton Capital Management's right to receive performance-based allocations and Bratton Capital Management and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line through direct or indirect limited partner and/or general partner interests in Neuro Line. Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to beneficially own the securities held by Neuro Line. Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Read SEC document |
| June 19, 2020 Filed Jun 23, 2020 21:41 UTC |
BRATTON DOUGLAS K10% owner
Neuro Line Partners LP10% owner
Bratton Capital Management, L.P.10% owner
Bratton Capital Inc.10% owner
|
SaleCommon Stock | 82,481 | $24.20 | $1,995,652.54 |
DisclosureSEC source: 0000899243-20-017498 · doc4.xml · nonDerivative · entry 1 BRATTON DOUGLAS K · CIK 0001281933 · 10% owner Neuro Line Partners LP · CIK 0001723842 · 10% owner Bratton Capital Management, L.P. · CIK 0001723787 · 10% owner Bratton Capital Inc. · CIK 0001723783 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Neuro Line Partners, L.P. Disclosed balance after: 870,554 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.61 to $24.60, inclusive. The reporting persons undertake to provide to Denali Therapeutics Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (4), (5), (6), (7) and (8). F2 · ownership.nature: These shares of common stock of the Issuer are held directly by Neuro Line Partners, L.P. ("Neuro Line"). The general partner of Neuro Line is Bratton Capital Management, L.P. ("Bratton Capital Management"). The general partner of Bratton Capital Management is Bratton Capital, Inc. ("Bratton Capital"). Douglas K. Bratton is the sole director of Bratton Capital. Neuro Line is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by Neuro Line. F3 · ownership.nature: (Continued from Footnote 2) In addition, Bratton Capital Management, Bratton Capital, and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line due to Bratton Capital Management's right to receive performance-based allocations and Bratton Capital Management and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line through direct or indirect limited partner and/or general partner interests in Neuro Line. Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to beneficially own the securities held by Neuro Line. Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.